share_log

Chardan Capital Reiterates Buy on Silence Therapeutics, Maintains $26 Price Target

Benzinga ·  Aug 17, 2023 07:47

Chardan Capital analyst Keay Nakae reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $26 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment